Advanced　prostate　cancer　is　regarded　as　a　fatal　disease,　characterized　by　limited　treatment　options,　poor　prognosis　and　considerable　tumor　metastasis　closely　related　to　angiogenesis.　Photodynamic　therapy　emerges　as　a　promising　and　safe　therapeutic　modality　for　advanced　prostate　cancer　with　high　metastasis　and　high　fatality　rate　due　to　its　focal　damage　to　tumor　cells,　as　well　as　its　anti-angiogenesis　and　antitumor　immunity　capabilities.　Herein,　a　tumor-targeting　vascular　disrupting　agent　ASA-404　was　introduced　to　conjugate　with　a　photosensitizer　ZnPc　for　targeted　prostate　cancer　treatment　and　enhanced　vascular-disrupting　efficiency.　Notably,　this　novel　organic　small-molecule　photosensitizer　Pc-ASA　possess　a　well-defined　chemical　structure　and　purity,　as　well　as　good　photophysical　and　photochemical　properties,　which　are　of　benefit　for　clinical　approval　and　application.　PcASA　prefers　to　accumulate　in　both　prostate　cancer　cells　and　vascular　endothelial　cells.　Moreover,　the　conjugation　of　ASA-404　boosts　the　photodynamic　anticancer　effect　of　Pc-ASA　towards　both　prostate　cancer　cells　and　vascular　endothelial　cells.　Ultimately,　PC-ASA　can　successfully　inhibit　the　migration　and　metastasis　of　prostate　cancer　cells,　offering　significant　advantages　in　advanced　prostate　cancer　management.　Our　study　might　open　a　window　in　the　development　of　the　tumor　and　vascular　dual-targeted　small-molecule　photosensitizers,　with　the　potential　to　achieve　safe　and　efficient　treatment　of　metastatic　advanced　prostate　cancer　through　dual　mode　of　antitumor　and　anti-vascular　action.